Cargando…

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is the most common primary brain cancer. GBMs commonly acquire resistance to standard-of-care therapies. Among the novel means to sensitize GBM to DNA-damaging therapies, a promising strategy is to combine them with inhibitors of the DNA damage repair (DDR) machinery, s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xavier, Mary-Ann, Rezende, Fernando, Titze-de-Almeida, Ricardo, Cornelissen, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394995/ https://www.ncbi.nlm.nih.gov/pubmed/34439854 http://dx.doi.org/10.3390/biom11081188

Ejemplares similares

Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness
por: Thompson, Timothy C., et al.
Publicado: (2017)

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
por: Engert, Florian, et al.
Publicado: (2016)

Development of a novel BRCAness score that predicts response to PARP inhibitors
por: Oshi, Masanori, et al.
Publicado: (2022)

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022)

PARP-1 protein expression in glioblastoma multiforme
por: Galia, A., et al.
Publicado: (2012)

BRCAness in prostate cancer
por: Bednarz-Knoll, Natalia, et al.
Publicado: (2019)

The BRCAness Landscape of Cancer
por: Guo, Maoni, et al.
Publicado: (2022)

Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas
por: Li, Hongyi, et al.
Publicado: (2020)

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
por: Ha, Kyungsoo, et al.
Publicado: (2014)

AURKA inhibition mimics BRCAness
por: Hirst, Jeff, et al.
Publicado: (2017)

Biomarkers for glioblastoma multiforme: status quo
por: Montano, Nicola, et al.
Publicado: (2016)

The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma
por: Morra, Francesco, et al.
Publicado: (2022)

Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample
por: Yoshida, Reiko, et al.
Publicado: (2021)

Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme
por: Lubanska, Dorota, et al.
Publicado: (2017)

Glioblastoma Multiforme
por: Sheehan, Jonas M., et al.
Publicado: (2012)

Genomic and Epigenomic Features of Glioblastoma Multiforme and its Biomarkers
por: Jadoon, Sarmad Sheraz, et al.
Publicado: (2022)

Biomarkers of Tumor Heterogeneity in Glioblastoma Multiforme Cohort of TCGA
por: Winkelmaier, Garrett, et al.
Publicado: (2023)

Glioblastoma multiforme – an overview
por: Urbańska, Kaja, et al.
Publicado: (2014)

Incidentalomas to glioblastoma multiforme
por: Sachdev, Bobby, et al.
Publicado: (2014)

Editorial: Molecular biology of biomarkers in diagnosis and treatment of glioblastoma multiforme
por: Zhao, Jianyi, et al.
Publicado: (2023)

Identification of LOX as a candidate prognostic biomarker in Glioblastoma multiforme
por: Liu, Erheng, et al.
Publicado: (2023)

In silico studies on marine actinomycetes as potential inhibitors for Glioblastoma multiforme
por: Kirubakaran, Palani, et al.
Publicado: (2011)

Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors
por: Yuan, Jie, et al.
Publicado: (2018)

BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence
por: Wysham, Weiya Z., et al.
Publicado: (2012)

BRCAness as a prognostic indicator in patients with early breast cancer
por: Liu, Lei, et al.
Publicado: (2020)

Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge
por: Caeiro, Cláudia, et al.
Publicado: (2022)

Tectal plate glioblastoma multiforme
por: Nemer, Michael D., et al.
Publicado: (2011)

Bilateral cystic glioblastoma multiforme
por: Kumar, Sushil, et al.
Publicado: (2013)

Glioblastoma Multiforme Stem Cells
por: Dimov, Irena, et al.
Publicado: (2011)

Atypical Presentation of Glioblastoma Multiforme
por: Al-Janabi, Wissam, et al.
Publicado: (2018)

Nanotechnology for Treatment of Glioblastoma Multiforme
por: Michael, Justin S., et al.
Publicado: (2018)

The complement system in glioblastoma multiforme
por: Bouwens van der Vlis, T. A. M., et al.
Publicado: (2018)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Survival Analysis of Glioblastoma Multiforme
por: Witthayanuwat, Supapan, et al.
Publicado: (2018)

Advances in Immunotherapy for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2017)

Targeted Nanotechnology in Glioblastoma Multiforme
por: Glaser, Talita, et al.
Publicado: (2017)

Prion Protein in Glioblastoma Multiforme
por: Ryskalin, Larisa, et al.
Publicado: (2019)

Current Immunotherapies for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2021)

Glioblastoma Multiforme Masquerading as Stroke
por: Remley, William, et al.
Publicado: (2021)

Advances in immunotherapy for glioblastoma multiforme
por: Mahmoud, Ahmad Bakur, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0ce249inbbpd86qjoor2lct7gk